Fujifilm Growth Strategy with the Acquisition of

Wako Pure Chemical Industries

FUJIFILM Holdings CorporationChairman and Chief Executive Officer

Shigetaka KomoriDecember 15, 2016

Expanding Business in Six Priority Areas

Healthcare

Optical Devices

DocumentSolutions

Graphic Systems

DigitalImaging

Key Business Areas

Highly FunctionalMaterials

Key Business Areas

1

Overview of Wako Pure Chemical Industries, Ltd.

2

Company Name： Wako Pure Chemical Industries, Ltd.

Incorporation： 1922

Chemicals Department of Takeda Pharmaceutical separated and established as Takeda Pure Chemical Ltd.

Business Overview： Manufacturing and sales of laboratory chemicals, clinical diagnostic reagents and specialitychemicals

Revenue： JPY 79.4 billion (FY2016/3, Consolidated)

Clinical Diagnostic Reagents JPY 26.0bn

Laboratory ChemicalsJPY 36.6bn

Speciality ChemicalsJPY 16.7bn

Objectives and Purposes of Acquisition

3

Healthcare

Optical Devices

Document Solutions

Graphic Systems

Digital Imaging

Highly Functional Materials

Key Business Areas

Clinical Diagnostic Reagents

SpecialityChemicals

Laboratory Chemicals

Objectives and Purposes of Acquisition

4

・Advancement of medical applications in regenerative medicines

・Improvement quality of medical care through widespread use of In-Vitro Diagnostics

・Stable supply of high quality pharmaceuticals through expansion of contract manufacturing

Technology fusion of Fujifilm and Wako

Healthcare Industrial・Contribution to advancement of cutting edge technology in semiconductor industry

・Creating innovation with development of new highly functional materials

Addressing Social Challenges

The Acquisition of Wako Pure Chemical Industries

FUJIFILM Holdings CorporationPresident and Chief Operation Officer

Kenji SukenoDecember 15, 2016

Business Overview of Wako Pure Chemical

6

Laboratory Chemicals Revenue: JPY36.6bn (46％ of total)related to: Cell culture medium DNA/Protein research Analysis of environment/food area Organic synthesis, etc.

Clinical Diagnostics Reagents Revenue: JPY26.0bn (33％ of total) For automated bio chemical analyzer, etc. For immune system and microorganism, etc.

Speciality Chemicals Revenue: JPY16.7bn (21％ of total) Semiconductor Materials (detergent for post CMP process, etc.) Azo polymerization initiator for superabsorbent polymer Pharmaceutical intermediate, etc.

Clinical Diagnostics ReagentsLaboratory Chemicals

Specialty Chemicals

Expected Synergies through the Acquisition

7

Expanding Healthcare Business1) Regenerative Medicine2) In-Vitro Diagnostics3) Pharmaceutical Contract Development and Manufacturing Organization(CDMO)

Expanding Highly Functional Materials Business1) Electronic Materials2) Industrial Products

The Three Key Components for Regenerative Medicine

8

Cell Culture MediumCytokine

Scaffold(recombinant peptide)

Cell

Fujifilm group to own all three key components for regenerative medicine

Regenerative Medicine Business

9

Expanding Regenerative

Medicine Business

GMP Certified Manufacturing

Facilities

Dispersion/Synthesis Technology

Cell Culture Medium

Manufacturing Technology

画像診断技術

Development/Manufacturing of

iPS Cell

Development/Manufacturing of

Regenerative Medicine Products

Patent & Know-how for Cell Production

and Cultivation

Scaffold(recombinant peptide)

10

In-Vitro Diagnosis (Medical System Business)

10

Clinical Chemical Analysis System

Immunodiagnosis System

Global Business Platform through Medical Devices

＜和光純薬＞免疫分析装置生化学分析試薬国内の営業網

Immune Analysis System

Laboratory Chemicals for Biochemical

Analysis

Extensive Sales Network with Access to

Clinical Facilities in Japan

Promoting In-Vitro Diagnostic ProductsDeveloping high-functional In-Vitro Diagnostic Products

Pharmaceutical CDMO (Pharmaceutical Business)

1111

Expanding Pharmaceutical CDMO

business

Chemical Synthesis Technology of Small

Molecule Drugs

Biopharmaceutical Manufacturing

Technology

Biopharmaceutical CDMO

FUJIFILM Finechemicals

Small Molecule Drugs CDMO

＜和光純薬＞免疫分析装置生化学分析試薬国内の営業網

Chemical Synthesis

Technology

Vast Sales Network to Capture Client Needs

Cell Culture Medium Manufacturing

Technology

Highly Functional Materials(Electronic Materials Business)

12

Photoresist

Materials for Image Sensor, etc.

CMP Slurry

＜和光純薬＞免疫分析装置生化学分析試薬国内の営業網

High Purity Cleaning Agent

Non-Ionic Surfactants, etc.

High QualityEtching Solution

Wafer (face down)

LoadCMP Slurry

Polishing Pad

Rotating PlateRotating Head

CMP Process

Accelerating Electronic Materials Business

＜和光純薬＞重合開始剤等＜和光純薬＞免疫分析装置生化学分析試薬国内の営業網

Polymerization Initiator

Domestic and Global Speciality Chemical Manufacturing Sites

Vast Polymeric Material

Highly Functional Materials Synergy(Industrial Products Business)

1313

Expanding Speciality Chemicals Business Globally

Library of 200,000 chemical

compounds

Chemical Synthesis

Technology

Analysis Technology

Strong Global Business Platform

1414

Overview of Acquisition

Acquisition Structure: Tender Offer for shares of Wako Pure Chemical Industries, Ltd. by FUJIFILM Corporation

Tender Offer Price: JPY 8,535 per share

Expected Amount of Funds Necessary for Tender Offer:Approximately JPY154.7 billion

Expected Schedule：

Feb.27 – Apr.3 Tender offer period for Wako shares

Apr.21 Settlement of Tender Offer (consolidation of Wako)

In the event of successful completion of the Tender Offer, Wako will be a consolidated subsidiary of Fujifilm Holdings on Apr. 21, 2017. Therefore, we expect no impact on Fujifilm Holdings’ FY2017/3 consolidated financial results. We will announce the impact for FY2018/3 consolidated financial results once details are confirmed.

15

To Achieve JPY 100billion in Revenue by FY2022/3

(JPY bn)

Laboratory Chemicals

Clinical Diagnostics

Reagents

Specialty Chemicals

Further Growth

Revenue Target of Wako Pure Chemical After Acquisition